Stock listing
Frankfurt:7PO Poxel SA Aktie
German listing (Frankfurt) of Poxel SA · home listing Euronext:POXEL
Follow Poxel SA into a list and get an email when it puts out news.
Share price · FWB:7PO
€0.131 EUR -0.006 (-4.4%)
Close on Nov 20, 2026
- Day range
- €0.131 – €0.131 EURNov 20, 2026
- Market cap
- €8.77M EURAt the close on Nov 20, 2026 · price × 66.96M shares outstanding
- 52-week range
- €0.123 – €0.382 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €6,588 EURMedian day 0 shares · 37 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Euronext:POXEL · Home | €0.126 EUR | -0.017 (-11.9%) | 1,242,193 | €0.140 | €0.140 | €0.126 | €0.143 | Close on Nov 20, 2026 |
| Frankfurt:7PO | €0.131 EUR | -0.006 (-4.4%) | — | €0.131 | €0.131 | €0.131 | €0.137 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:7PO · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.145 | -0.009 | -5.8% | €0.145 | €0.145 | €0.145 | 0 | |
| €0.154 | +0.006 | +4.1% | €0.154 | €0.154 | €0.154 | 78,000 | |
| €0.148 | -0.005 | -3.3% | €0.148 | €0.148 | €0.148 | 78,000 | |
| €0.153 | -0.005 | -3.2% | €0.153 | €0.153 | €0.153 | 0 | |
| €0.158 | -0.004 | -2.5% | €0.158 | €0.158 | €0.158 | 0 | |
| €0.162 | +0.002 | +1.3% | €0.162 | €0.162 | €0.162 | 1,726 | |
| €0.160 | +0.005 | +3.2% | €0.160 | €0.160 | €0.160 | 444,362 | |
| €0.155 | -0.006 | -3.7% | €0.155 | €0.155 | €0.155 | 61,710 | |
| €0.161 | -0.005 | -3.0% | €0.160 | €0.162 | €0.158 | 0 | |
| €0.166 | -0.006 | -3.5% | €0.166 | €0.166 | €0.166 | 33,154 | |
| €0.172 | -0.013 | -7.0% | €0.172 | €0.172 | €0.172 | 180,532 | |
| €0.185 | -0.005 | -2.6% | €0.185 | €0.185 | €0.185 | 0 | |
| €0.190 | +0.008 | +4.4% | €0.190 | €0.190 | €0.190 | 0 | |
| €0.182 | +0.028 | +18.2% | €0.189 | €0.189 | €0.181 | 8,600 | |
| €0.154 | +0.005 | +3.4% | €0.142 | €0.156 | €0.141 | 10,000 | |
| €0.149 | -0.004 | -2.6% | €0.149 | €0.149 | €0.149 | 0 | |
| €0.153 | -0.004 | -2.5% | €0.153 | €0.153 | €0.153 | 0 | |
| €0.157 | +0.027 | +20.8% | €0.157 | €0.157 | €0.157 | 6,180 | |
| €0.130 | 0.000 | 0.0% | €0.130 | €0.130 | €0.130 | 0 | |
| €0.130 | +0.002 | +1.6% | €0.130 | €0.130 | €0.130 | 0 | |
| €0.128 | -0.002 | -1.5% | €0.128 | €0.128 | €0.128 | 63,516 | |
| €0.130 | +0.002 | +1.6% | €0.130 | €0.130 | €0.130 | 40,420 | |
| €0.128 | +0.004 | +3.2% | €0.129 | €0.129 | €0.128 | 0 | |
| €0.124 | -0.003 | -2.4% | €0.129 | €0.131 | €0.123 | 0 | |
| €0.127 | -0.032 | -20.1% | €0.142 | €0.143 | €0.127 | 0 | |
| €0.159 | -0.004 | -2.5% | €0.159 | €0.159 | €0.159 | 115,692 | |
| €0.163 | -0.001 | -0.6% | €0.163 | €0.163 | €0.163 | 0 | |
| €0.164 | -0.005 | -3.0% | €0.164 | €0.164 | €0.164 | 0 | |
| €0.169 | -0.003 | -1.7% | €0.169 | €0.169 | €0.169 | 0 | |
| €0.172 | -0.001 | -0.6% | €0.172 | €0.172 | €0.172 | 0 | |
| €0.173 | +0.003 | +1.8% | €0.166 | €0.175 | €0.166 | 259,424 | |
| €0.170 | -0.016 | -8.6% | €0.170 | €0.170 | €0.170 | 0 | |
| €0.186 | +0.012 | +6.9% | €0.186 | €0.186 | €0.186 | 0 | |
| €0.174 | +0.019 | +12.3% | €0.174 | €0.174 | €0.174 | 0 | |
| €0.155 | -0.001 | -0.6% | €0.155 | €0.155 | €0.155 | 0 | |
| €0.156 | +0.004 | +2.6% | €0.156 | €0.156 | €0.156 | 4,000 | |
| €0.152 | -0.020 | -11.6% | €0.152 | €0.152 | €0.152 | 0 | |
| €0.172 | +0.003 | +1.8% | €0.172 | €0.172 | €0.172 | 0 | |
| €0.169 | -0.005 | -2.9% | €0.169 | €0.169 | €0.169 | 0 | |
| €0.174 | -0.003 | -1.7% | €0.174 | €0.174 | €0.174 | 0 | |
| €0.177 | -0.002 | -1.1% | €0.177 | €0.177 | €0.177 | 106,800 | |
| €0.179 | +0.001 | +0.6% | €0.177 | €0.181 | €0.177 | 0 | |
| €0.178 | -0.007 | -3.8% | €0.178 | €0.178 | €0.178 | 0 | |
| €0.185 | -0.002 | -1.1% | €0.185 | €0.185 | €0.185 | 0 | |
| €0.187 | -0.006 | -3.1% | €0.187 | €0.187 | €0.187 | 0 | |
| €0.193 | +0.002 | +1.0% | €0.193 | €0.193 | €0.193 | 513,720 | |
| €0.191 | -0.001 | -0.5% | €0.188 | €0.192 | €0.187 | 0 | |
| €0.192 | -0.003 | -1.5% | €0.192 | €0.192 | €0.192 | 0 | |
| €0.195 | +0.002 | +1.0% | €0.196 | €0.197 | €0.195 | 0 | |
| €0.193 | +0.001 | +0.5% | €0.193 | €0.193 | €0.193 | 0 | |
| €0.192 | -0.007 | -3.5% | €0.192 | €0.192 | €0.192 | 116,422 | |
| €0.199 | -0.006 | -2.9% | €0.199 | €0.199 | €0.199 | 0 | |
| €0.205 | -0.020 | -8.9% | €0.205 | €0.205 | €0.205 | 0 | |
| €0.225 | +0.033 | +17.2% | €0.225 | €0.225 | €0.225 | 10,000 | |
| €0.192 | -0.003 | -1.5% | €0.192 | €0.192 | €0.192 | 0 | |
| €0.195 | +0.008 | +4.3% | €0.195 | €0.195 | €0.195 | 53,722 | |
| €0.187 | -0.003 | -1.6% | €0.196 | €0.196 | €0.186 | 0 |
- Ticker
- Frankfurt:7PO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 9, 2026
Poxel nombre d’actions et de droits de vote composant le capital social
Latest news
Poxel Reports Revenue for the Third Quarter of 2026
Oct 19, 2026
Closed €0.154 (+3.4%) on Oct 19, 2026
Mise à disposition de la Lettre aux Actionnaires de Poxel
Oct 12, 2026
Closed €0.13 (+1.6%) on Oct 12, 2026
Laure-Hélène Mercier Co-Opted as Chair of the Board of Directors of Poxel
Sep 3, 2026
Closed €0.193 (+1.0%) on Sep 4, 2026
Poxel Publishes Its Turnover for the Second Quarter of 2026 and Announces the Postponement of the Publication of Its 2025 Financial Statements
Jul 30, 2026
Closed €0.204 (+3.0%) on Jul 31, 2026
Poxel Appoints Yves Decadt as Chief Executive Officer to Accelerate Portfolio Development and Strategic Partnerships
Jun 10, 2026
Closed €0.222 (+2.3%) on Jun 11, 2026
Poxel Reports First Quarter 2026 Revenue and Provides a Business Update
May 20, 2026
Closed €0.251 (+2.9%) on May 20, 2026
Poxel: Postponement of the Publication of the 2025 Annual Financial Statements and the Annual Financial Report
Apr 30, 2026
Closed €0.253 (+1.6%) on May 4, 2026
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
Mar 31, 2026
Closed €0.224 (-1.8%) on Mar 31, 2026
Poxel Confirms the Drawdown Under the Additional Tranche D PDR Bond Issue as Part of the Continuation Plan
Mar 25, 2026
Closed €0.234 (+1.3%) on Mar 26, 2026
Poxel SA on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 34 in all · newest Nov 9, 2026 · oldest 2025
- Decks
- 13 decks · latest Oct 16, 2025
Where Poxel SA is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Euronext:POXEL · Home listing | Euronext | France | EUR |
| LSIN:0RA2 | LSIN | United Kingdom | EUR |
| Lang & Schwarz:A14M04 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A14M04 | LS Exchange | Germany | EUR |
| Frankfurt:7PO · This page | Frankfurt | Germany | EUR |
| OTC:PXXLF | OTC | United States | USD |
| Aquis:POXELP | Aquis | United Kingdom | EUR |
| Aquis:POXELP | Aquis | United Kingdom | EUR |
| Dusseldorf:7PO | Dusseldorf | Germany | EUR |
| gettex:7PO | gettex | Germany | EUR |
| Hamburg:7PO | Hamburg | Germany | EUR |
| Munich:7PO | Munich | Germany | EUR |
| Stuttgart:7PO | Stuttgart | Germany | EUR |
| Turquoise:POXELP | Turquoise | United Kingdom | EUR |
Valuation
balance Jun 30, 2025 · price Nov 20, 2026
- Enterprise value
- €67.38M EUR
- P/E
- Not reported
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Poxel SA · EURONEXT:POXEL | US$9.27M | US$73.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Purple Biotech Ltd. · TASE:PPBT | US$9.70M | US$3.73M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Jasper Therapeutics, Inc. · NASDAQ:JSPR | US$9.64M | −US$125.6M | n/a | −15.7× | n/a | n/a | n/a | n/a | 2.02 |
| Alzinova AB · OMXSTO:ALZ | US$9.58M | US$8.35M | n/a | 17.0× | n/a | 0.6× | −484.4% | 0.0× | n/a |
| Chemomab Therapeutics Ltd. · NASDAQ:CMMB | US$9.58M | US$4.92M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.04 |
| Genvor Incorporated · OTC:GNVR | US$9.47M | US$9.27M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| TScan Therapeutics, Inc. · NASDAQ:TCRX | US$9.27M | −US$30.80M | n/a | −5.9× | n/a | 0.2× | n/a | 0.9× | 1.66 |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| CytoMed Therapeutics Limited · NASDAQ:GDTC | US$9.01M | US$8.23M | n/a | 14.7× | n/a | 2.3× | −730.3% | 0.1× | 0.16 |
| PreveCeutical Medical Inc · CSE:PREV | US$8.97M | US$8.95M | n/a | n/a | n/a | n/a | n/a | n/a | 0.73 |
| BioLineRX Ltd. · TASE:BLRX | US$8.90M | US$10.13M | n/a | 8.6× | n/a | 0.5× | −171.7% | 0.3× | n/a |
| Median of the others | US$9.37M | US$8.29M | 6.8× | 0.7× | −328.0% | 0.1× | 0.73 |
Team and board
Officers
| Officer | Role |
|---|---|
| Yves Decadt | Chief Executive Officer |
| Antoine de Boissieu | Chief Financial Officer |
| Alexandre Massias | Investor Relations / Media |
| Aurélie Manavarere | Investor Relations / Media |
| Paul Boivin | Investor relations / Media |
| Théo Martin | Investor relations / Media |
| Thomas Cozzolino | Investor relations / Media |
Board
| Director | Role |
|---|---|
| Laure-Hélène Mercier | Chair of the Board of Directors |
| Amit Kohli | Independent Director |
| Yves Decadt | Chief Executive Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Dec 31, 2025 | Mar 25, 2026 | +2.7% |
| Quarter to Sep 30, 2025 | Nov 7, 2025 | +10.5% |
| Q2 2025 | Sep 23, 2025 | +1.3% |
| Quarter to Mar 31, 2025 | Apr 22, 2025 | +14.0% |
| Quarter to Sep 30, 2024 | Oct 3, 2024 | +12.3% |
| Quarter to Mar 31, 2024 | May 16, 2024 | −4.9% |
| Q4 2023 | Feb 15, 2024 · After close | −0.4% |
| Quarter to Sep 30, 2023 | Nov 8, 2023 · After close | −0.3% |
| Q2 2023 | Aug 30, 2023 · After close | −4.8% |
| Q1 2023 | May 3, 2023 · After close | −0.3% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2022 | Mar 23, 2023 · Before open | −3.3% |
| Q3 2022 | Oct 4, 2022 · After close | −5.8% |
| Q2 2022 | Aug 8, 2022 · After close | +13.0% |
| Q1 2022 | May 17, 2022 · After close | +2.9% |
| Q4 2021 | Mar 23, 2022 | −19.1% |
| Q3 2021 | Oct 20, 2021 · After close | −0.7% |
| Q2 2021 | Jul 21, 2021 · After close | +1.3% |
| Q1 2021 | Apr 21, 2021 · After close | 0.0% |
| Q4 2020 | Mar 24, 2021 · After close | −0.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| FY2024 Earnings Presentation | Earnings | 17 slides | Oct 16, 2025 |
| Investor Presentation (December 2024) | Investor deck | 36 slides | December 2024 |
| FY2023 Earnings Presentation | Earnings | 27 slides | Oct 3, 2024 |
| H1 2023 Earnings Presentation | Earnings | 33 slides | Sep 26, 2023 |
| FY2022 Earnings Presentation | Earnings | 38 slides | Mar 23, 2023 |
| H1 2022 Earnings Presentation | Earnings | 43 slides | Sep 21, 2022 |
| FY2021 Earnings Presentation | Earnings | 27 slides | Mar 22, 2022 |
| H1 2021 Earnings Presentation | Earnings | 30 slides | Sep 23, 2021 |
| Investor Presentation (July 2021) | Investor deck | 33 slides | Jul 12, 2021 |
| FY2020 Earnings Presentation | Earnings | 42 slides | Mar 25, 2021 |
All 13 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (October 2020) | Technical | 19 slides | Oct 1, 2020 |
| H1 2020 Earnings Presentation | Earnings | 28 slides | Sep 15, 2020 |
| Technical Presentation (September 2016) | Technical | 13 slides | Sep 14, 2016 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Rights offering of new shares (capital increase with preemptive subscription rights) Update: rights offering Buyers: IPF (guarantees the capital increase, subject to not exceeding 29.9% of the Company's share capital following the transaction); IPF Invest Co 2 S.à.r.l. (guarantees the capital increase with preemptive subscription rights) | Apr 30, 2026 | |
| At-the-market programme of warrants to subscribe new ordinary shares (SmartATM equity line) Update: at-the-market programme Buyers: IRIS (Subscribed 40 million warrants; financing commitment of up to €5 million over five years in twenty €250,000 quarterly tranches) Insiders: The equity line does not create any conflict of interest for directors or corporate officers Use of proceeds: Secure the financial foundation needed to implement the company's recovery plan; part of the restructuring of IRIS bond debt | Feb 3, 2026 | |
| Bonds (IPF bond loan) Tranche closed: €500,000 raised Buyers: IPF Partners (bond issue for a maximum amount of €2.5 million under an additional Tranche D of the IPF bond loan); IPF (new bond borrowings of €3.75 million, in addition to €2.5 million of bonds issued during the observation period) Use of proceeds: Fund Poxel's financing needs under the recovery plan until it generates positive cash flow | Jan 30, 2026 | US$586,560 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in EUR
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.64M | 1.98M | 674.0K | 13.4M | 6.81M | 26.6M | 74.6M | 5.29M | 70.3K | 59.6K |
| Cost of revenue | 2.94M | 1.98M | 672.0K | 59.0K | 0 | 0 | 0 | 0 | 25.2K | |
| Gross profit | 3.69M | 1.00K | 2.00K | 13.3M | 6.81M | 26.6M | 74.6M | 5.29M | 70.3K | 34.5K |
| Research and development | 1.00M | 21.0M | 13.9M | 27.5M | 29.2M | 44.5M | 58.1M | 24.1M | 20.9M | 9.24M |
| Selling, general and administrative | 5.03M | 4.44M | 10.6M | 9.94M | 7.41M | 4.49M | 3.45M | 3.83M | 2.68M | |
| Operating income | -3.50M | -28.8M | -21.9M | -22.5M | -29.8M | -24.7M | 12.5M | -21.9M | -24.3M | -11.7M |
| Depreciation and amortization | 17.2M | 555.0K | 556.0K | 551.0K | 424.0K | 62.0K | 37.9K | 32.0K | 23.0K | |
| EBITDA | -11.6M | -21.3M | -21.9M | -29.3M | -24.2M | 12.6M | -21.9M | -24.3M | -11.7M | |
| Interest expense | 14.0M | 6.15M | 9.91M | 2.95M | 1.73M | 233.0K | 28.0K | 46.5K | 572.4K | 918.8K |
| Income before tax | -18.3M | -35.1M | -31.4M | -23.8M | -31.8M | -25.7M | 13.6M | -22.3M | -24.5M | -12.2M |
| Income tax | 2.00K | 2.00K | 2.00K | 2.00K | 36.0K | 1.00K | 77.0K | 395.9K | 200.6K | -124.2K |
| Net income | -18.3M | -35.1M | -31.4M | -23.8M | -31.8M | -25.7M | 13.5M | -22.7M | -24.5M | -12.2M |
| Earnings per share, basic | -0.38 | -1.05 | -1.08 | -0.83 | -1.16 | -0.99 | 0.54 | -0.99 | -1.16 | -0.68 |
| Earnings per share, diluted | -0.38 | -1.05 | -1.08 | -0.83 | -1.16 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.66M | 2.34M | 13.1M | 32.3M | 40.2M | 37.2M | 66.7M | 54.2M | 45.6M | 42.4M |
| Short-term investments | -86.0K | -193.0K | 3.53M | 24.6M | 19.0M | 59.4M | 50.0M | -184.3K | ||
| Receivables | 4.62M | 385.0K | 394.0K | 50.0K | 281.0K | 14.8M | 15.6M | 11.5M | 3.88M | 2.54M |
| Inventory | -1.56M | 0 | 1 | 898.0K | 1 | 552.3K | 617 | 226 | ||
| Current assets | 14.9M | 4.52M | 16.6M | 36.3M | 46.0M | 52.9M | 88.3M | 66.3M | 49.6M | 46.2M |
| Property, plant and equipment | 121.0K | 1.32M | 1.72M | 2.22M | 2.32M | 296.0K | 143.0K | 145.4K | 152.7K | |
| Total assets | 14.9M | 4.82M | 34.7M | 54.9M | 65.1M | 72.3M | 105.5M | 66.8M | 50.3M | 46.8M |
| Accounts payable | 2.05M | 3.30M | 4.41M | 8.42M | 8.36M | 10.2M | 8.65M | 3.25M | 4.92M | 2.82M |
| Current liabilities | 19.0M | 13.3M | 27.4M | 15.9M | 16.5M | 30.8M | 49.1M | 46.6M | 10.1M | 7.14M |
| Long-term debt | 40.1M | 24.5M | 29.0M | 19.5M | 62.0K | 359.0K | 555.0K | 708.6K | 1.55M | |
| Total debt | 47.0M | 43.4M | 35.1M | 23.6M | 7.70M | 14.2M | 1.31M | 1.58M | 3.15M | |
| Total liabilities | 53.9M | 53.0M | 46.7M | 38.2M | 33.2M | 49.7M | 47.4M | 10.9M | 8.82M | |
| Shareholders' equity | -58.9M | -49.1M | -18.2M | 8.21M | 27.1M | 39.1M | 55.8M | 19.3M | 39.4M | 38.0M |
| Shares outstanding | 38.6M | 29.1M | 28.6M | 27.5M | 25.9M | 24.8M | 23.0M | 21.1M | 17.9M |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.51M | -14.0M | -21.8M | -16.9M | -25.7M | -25.7M | -4.74M | 8.13M | -18.8M | -10.1M |
| Capital spending | -17.0M | -11.0K | -28.0K | -235.0K | -113.0K | -7.88M | -35.8K | -24.6K | -143.9K | |
| Free cash flow | 3.05M | -21.8M | -16.9M | -26.0M | -25.8M | -12.6M | 8.09M | -18.9M | -10.2M | |
| Cash from investing | 92.0K | 41.0K | 0 | -42.0K | 52.0K | 352.0K | -7.61M | 213.1K | 179.8K | 96.9K |
| Cash from financing | 10.7M | 3.23M | 2.58M | 9.03M | 28.7M | -4.21M | 25.7M | -496.0K | 21.8M | 42.1M |
| Dividends paid | -250.0K | |||||||||
| Share buybacks | 0 | 295.0K | 16.9M | 1.03M | 12.2M | 546.0K | 26.8M | -250.0K | ||
| Change in cash | 1.31M | -10.7M | -19.2M | -7.92M | 3.02M | -29.6M | 13.3M | 7.84M | 3.16M | 32.2M |
Cap table
Built by 6ix from Poxel SA’s releases · as of Sep 29, 2025
- Common shares
- 66,959,377
- Fully diluted
- 66,959,377
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 66,959,377 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 66,959,377 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alexandre Massias | Investor Relations / Media · Since at least Sep 3, 2026 |
| Amit Kohli | Independent Director · Since at least Aug 1, 2025 |
| Antoine de Boissieu | Chief Financial Officer · Since at least Nov 5, 2026 |
| Arthur Rouillé | Investor relations / Media · Dec 10, 2025 – Nov 5, 2026 · Past |
| Aurélie Manavarere | Investor Relations / Media · Since at least Nov 20, 2025 |
| Laure-Hélène Mercier | Chair of the Board of Directors · Since at least Sep 3, 2026 |
| Paul Boivin | Investor relations / Media · Since at least Feb 16, 2026 |
| Théo Martin | Investor relations / Media · Since at least Jun 10, 2026 |
| Thomas Cozzolino | Investor relations / Media · Since at least Apr 30, 2026 |
| Yves Decadt | Chief Executive Officer · Since Jun 10, 2026 |
Log in to ask 6ix AI your own questions about Poxel SA.